Literature DB >> 17381186

Naturalistic treatment of Alzheimer's disease with galantamine: 12-month follow-up from the NATURE study.

Henry Brodaty, Michael Woodward, Karyn Boundy, Nicola Barnes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17381186     DOI： 10.2165/00023210-200721040-00006

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


× No keyword cloud information.
  2 in total

1.  A naturalistic study of galantamine for Alzheimer's disease.

Authors:  Henry Brodaty; Michael Woodward; Karyn Boundy; Nicola Barnes; Gabrielle Allen
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.

Authors:  Murray A Raskind; Elaine R Peskind; Luc Truyen; Paul Kershaw; ChandrasekharRao Venkata Damaraju
Journal:  Arch Neurol       Date:  2004-02
  2 in total
  3 in total

1.  Long-term course and effectiveness of combination therapy in Alzheimer disease.

Authors:  Alireza Atri; Lynn W Shaughnessy; Joseph J Locascio; John H Growdon
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

2.  Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease.

Authors:  Carolyn W Zhu; Elayne E Livote; Nikolaos Scarmeas; Marilyn Albert; Jason Brandt; Deborah Blacker; Mary Sano; Yaakov Stern
Journal:  Alzheimers Dement       Date:  2013-01-17       Impact factor: 21.566

3.  A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression.

Authors:  Mary Sherman Mittelman; Henry Brodaty; Aaron Seth Wallen; Alistair Burns
Journal:  Am J Geriatr Psychiatry       Date:  2008-11       Impact factor: 4.105
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.